University of Vermont and UVM Health Network Participate in Phase 3 COVID-19 Vaccine Trial
October 29, 2020
October 29, 2020
BURLINGTON, Vermont, Oct. 29 -- The University of Vermont issued the following news:
The University of Vermont Medical Center and Vaccine Testing Center at the University of Vermont's Larner College of Medicine have been selected to take part in a Phase 3 trial for a COVID-19 vaccine developed by Oxford University and manufactured by AstraZeneca.
The AZD1222 COVID-19 VACCINE Study is researching an investigational vaccine for the prevention of COVID-19, the disease . . .
The University of Vermont Medical Center and Vaccine Testing Center at the University of Vermont's Larner College of Medicine have been selected to take part in a Phase 3 trial for a COVID-19 vaccine developed by Oxford University and manufactured by AstraZeneca.
The AZD1222 COVID-19 VACCINE Study is researching an investigational vaccine for the prevention of COVID-19, the disease . . .